Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Synthesis method of imatinib and imatinib mesylate

A technology of methanesulfonate and synthesis method, applied in the directions of sulfonate preparation, organic chemistry, etc., can solve the problems of long production cycle, increased cost, complicated and complicated post-processing, etc., and achieve the effect of reducing dosage

Pending Publication Date: 2020-04-21
杭州沧海帆医药科技有限公司
View PDF16 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] There are many domestic and foreign literature reports about the synthetic method of Gleevec. The earliest report is found in European patent EP564409 (the route is as follows), which uses 2-methyl-5-nitroaniline as raw material, and 3-dimethylamino-1 -(3-pyridyl)-2-propen-1-one reacts into a pyrimidine ring, and then prepares imatinib through palladium-carbon catalytic reduction and amidation. The main disadvantages of this method are: 1. Forming a pyrimidine ring and amidation The yield of two steps is low, 2. Catalyzed hydrogenation has potential safety hazard in large-scale industrial production 3. Acylating agent also needs five-step synthesis, therefore, whole process route is long, yield is low, raw material utilization rate is low, and production cost High, poor economy and does not meet the requirements of green chemistry
[0006] Chinese patent CN200810033189.9 (the route is as follows) uses N-(4-methyl-3-aminophenyl)-4-(4-methyl-piperazinyl-1-methyl)-benzamide as raw material and 4-Methyl-(3-pyridyl)-2-pyrimidinone can obtain imatinib under the action of condensing agent and alkali, but the condensing agent is expensive, low temperature needs to be controlled, post-treatment is only washed with water, and the product impurities are difficult to remove and other shortcomings, not conducive to industrial production
[0011] The synthetic method disclosed in Chinese patent CN03803556.1 is to use 3-bromo-4-methylaniline as raw material to obtain imatinib by using trimethylaluminum aminolysis, and then obtain imatinib by palladium catalyst and BINAP ligand. The disadvantage of this method is that the final There are isomers in the product, which increases the difficulty and cost of separation and purification; the flammable chemical trimethylaluminum and expensive palladium catalyst are used to catalyze hydrogenation, which brings potential safety risks to large-scale industrial production; in addition, the ligand BINAP The price is also more expensive; these have increased the cost of industrialization, making the process less economical
[0013] 此外,CN200710067344.4,、WO2006071130、WO2008098949、 WO2009151899、US2010076189、US2008255138、WO2008070350、 US20080207904等专利以及A Facile TotalSynthesis of Imatinib Base and Its Analogues(Organic Process Research&Development 2008,12, 490–495)、甲磺酸伊马 The synthesis of Tini (Chinese Journal of Pharmaceutical Sciences, 2008, 43 (3), 228-229) and other documents have proposed new methods or improved the synthesis of Gleevec, but there are still many shortcomings, such as using highly toxic, Reagents that are harmful to the environment, or expensive catalysts, have harsh reaction conditions, long process routes, high raw material costs, high pollution, high energy consumption, long production cycles, cumbersome and complicated post-processing, and low product purity. Methyl imatinib is difficult to remove, and the total yield is low, which will increase the difficulty and cost of industrial production and reduce the economics of industrialization

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthesis method of imatinib and imatinib mesylate
  • Synthesis method of imatinib and imatinib mesylate
  • Synthesis method of imatinib and imatinib mesylate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Example 1 Synthesis of 3-dimethylamino-1-(3-pyridyl)-2-propen-1-one

[0066] Add 96.91g of 3-acetylpyridine and 104.86g of N,N-dimethylamide dimethyl acetal into a 500ml round-bottomed flask, raise the temperature to 85°C and react for 8h. After the reaction, unreacted N , N-dimethylamide dimethyl acetal, cooled and crystallized, filtered with suction, washed the filter cake with ether, and dried naturally to obtain 132.89 g of a yellow-brown solid with a yield of 94.38%.

[0067] Mp: 81~82℃

[0068] 1 H-NMR (CDCl 3 )δ: 9.05 (1H, d, J = 1.6Hz), 8.68 (1H, dd, J = 4.8, 1.6 Hz), 8.21 (1H, m), 7.86 (1H, d, J = 12.2Hz,), 7.37 (1H,dd,J=7.3, 4.8Hz), 5.69(1H,d,J=12.2Hz), 3.20(3H,s), 2.97(3H,s).

[0069] MS:177.3(M+H)

[0070] Purity: TLC (ethyl acetate: petroleum ether = 1:1) single point

[0071] Add 1.45kg of 3-acetylpyridine and 1.57kg of N,N-dimethylamide dimethyl acetal to a 10L reaction kettle respectively, raise the temperature to 85°C and react for 10h. After the re...

Embodiment 2

[0072] Example 2 Synthesis of 2-methyl-5-nitrophenylguanidine nitrate

[0073] Throw 121.72g of 2-methyl-5-nitroaniline into the medium, then throw 100.8g of 50% NH 2 CN, add 160ml of ethanol, stir and heat up to 70°C, then add 118ml of concentrated hydrochloric acid dropwise into the three-necked flask, reflux for 3 hours after the dropwise addition, after the reaction, cool down to 45°C, pour 50ml of concentrated HNO 3 Continue to stir for about 1 min, let stand to cool down and crystallize, filter with suction, wash the filter cake with 150 ml of ethanol, and dry to obtain 179.16 g of yellow-white solid with a yield of 87.07%.

[0074] Mp: 210~211℃

[0075] 1 H-NMR (DMSO-d 6 )δ: 8.63-8.64 (1H, br), 7.21-7.27 (1H, m), 6.72-6.76 (1H, d, J = 1.6Hz), 6.69 (3H, s), 1.43 (3H, s)

[0076] MS:195.2(M+H)

[0077] Throw 2.43kg of 2-methyl-5-nitroaniline into a 20L reactor, and then throw 2.12kg of 50% NH 2 CN, add 2.5L ethanol, stir and heat up to 70°C, then add 2.3L concentrat...

Embodiment 3

[0078] Example 3 Synthesis of N-(2-methyl-5-nitrophenyl)-4-(3-pyridyl)-2-pyrimidinamine

[0079] Throw 52.8g of 3-dimethylamino-1-(3-pyridyl)-2-propen-1-one into a three-necked flask, then throw 300ml of ethanol and stir until it is completely dissolved, then add 2-methyl-5 -Nitrophenylguanidine nitrate 77.16g, add 19.44g KOH, react under reflux for 18h, cool to room temperature after the reaction, filter with suction, and wash the filter cake with 50ml of isopropanol, then wash with water until the filtrate is neutral and colorless, dry 80.01 g of yellow-white solid was obtained, and the yield was 86.87%.

[0080] Mp: 193~194℃

[0081] 1 H-NMR (CDCl 3 )δ: 9.48(1H, s), 9.27(1H, s), 8.76-8.74(1H, m), 8.54-8.60(2H, m), 7.85-7.88(1H, m), 7.49-7.52(1H, m), 7.36-7.32 (2H, m), 7.18 (1H, s) 2.48 (3H, s).

[0082] MS:308.3(M+H)

[0083] Purity: TLC (ethyl acetate: acetone = 4:1) single point

[0084] Throw 1.06kg of 3-dimethylamino-1-(3-pyridyl)-2-propen-1-one into the kettle, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Wavelengthaaaaaaaaaa
Login to View More

Abstract

The invention relates to a synthesis method of imatinib and imatinib mesylate. The method comprises the following steps: condensing 3-acetylpyridine and N,N-dimethylformamide dimethyl acetal which aretaken as initial raw materials to obtain 3-dimethylamino-1-(3-pyridyl)-2-propen-1-one, then reacting with 2-methyl-5-nitrophenylguanidine nitrate to form a pyrimidine ring, performing nitro reductionto obtain N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinamine, amidating the N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinamine and 4-(chloromethyl)benzoyl chloride, performing affinitysubstitution with 1-methylpiperazine to obtain imatinib, and salifying the imatinib and methanesulfonic acid. The products obtained by the method have the advantages of few impurities, simplicity in post-treatment, high total yield, greenness, environmental protection and safety, and is suitable for a production process for large-scale industrial production of imatinib mesylate.

Description

technical field [0001] The invention relates to the technical field of medicine synthesis technology, in particular to a synthesis technology of imatinib and its medicinal mesylate suitable for large-scale industrial production. Background technique [0002] Imatinib mesylate (STI 571) is a successful tyrosine kinase inhibitor researched by Novartis, Switzerland, for chronic myeloid leukemia (CML) and gastrointestinal stromal cell tumor (GIST) )Treatment. In May 2001, imatinib mesylate was approved by the FDA for marketing, and its trade name is Glivec. It is currently an isolated drug in the United States, Japan, and Europe, and it is a first-line drug for the treatment of leukemia. The chemical name of imatinib mesylate is 4-[(4-methyl-1-piperazine)methyl]-4-[4-methyl-3-[[4-(3-pyridyl)-2 -pyrimidinyl]amino]-phenyl]benzamide methanesulfonate, the chemical structure is: [0003] [0004] There are many domestic and foreign literature reports on the synthetic method of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D401/04C07C303/32C07C309/04
CPCC07C303/32C07D401/04C07C309/04
Inventor 赵海峰
Owner 杭州沧海帆医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products